We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 01, 2022

Efficacy of an Alternative Schedule of Palbociclib in Reducing the Incidence of Grade 3 or Above Neutropenia

NPJ breast cancer


Additional Info

NPJ breast cancer
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
NPJ Breast Cancer 2022 Mar 21;8(1)35, J Krishnamurthy, J Luo, R Suresh, F Ademuyiwa, C Rigden, T Rearden, K Clifton, K Weilbaecher, A Frith, A Roshal, PK Tandra, M Cherian, T Summa, B Haas, S Thomas, L Hernandez-Aya, M Bergqvist, L Peterson, CX Ma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading